Mice treated with MCC950, a specific NLRP3 inhibitor, experienced resolution of acute or chronic colitis by inhibiting ASC oligomerization, caspase-1 dependent activation of IL-1β and IL-18, and reducing pro-inflammatory cytokines (Perera et al., 2018; Wu et al., 2018). This evidence concerns the gene IL18 and colitis.